Leerink Partnrs Analysts Raise Earnings Estimates for Waters
Research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Waters in a note issued to investors on ...
Leerink Partnrs Has Strong Estimate for TVTX FY2026 Earnings
Analysts at Leerink Partnrs raised their FY2026 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz ...
Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...
Crain's New York18h
Drugmakers step back from diversity pledges in bow to Trump
Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...
Doximity, Inc. (DOCS): Among the Health Information Services Stocks Outpacing the Market in 2025
We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...